Immune monitoring for advanced cell therapy trials in transplantation: which assays and when?

Immune monitoring for advanced cell therapy trials in transplantation: which assays and when?

A number of immune regulatory cellular therapies, including regulatory T cells and mesenchymal stromal cells, have emerged as novel alternative therapies for the control of transplant alloresponses. Clinical studies have demonstrated their feasibility and safety, however developing our understanding...

Bibliografske podrobnosti
Main Authors:	Stark, HL, Wang, HC, Kuburic, J, Alzhrani, A, Hester, J, Issa, F
Format:	Journal article
Jezik:	English
Izdano:	Frontiers Media 2021

Podobne knjige/članki

Immune Monitoring for Advanced Cell Therapy Trials in Transplantation: Which Assays and When?
od: Helen L. Stark, et al.
Izdano: (2021-03-01)

An exploration of regulatory T cells in transplantation: cell therapy development and immune monitoring
od: Alzhrani, AI
Izdano: (2021)

Biomarkers and surrogates of acute rejection in vascularized composite allograft transplantation
od: Honeyman, C, et al.
Izdano: (2021)

Biomarker and surrogate development in vascularised composite allograft transplantation: current progress and future challenges
od: Honeyman, C, et al.
Izdano: (2020)

Immune Monitoring Assay for Extracorporeal Photopheresis Treatment Optimization After Heart Transplantation
od: Maja-Theresa Dieterlen, et al.
Izdano: (2021-08-01)

Feasibility, long‐term safety and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients
od: Harden, PN, et al.
Izdano: (2020)

Regulatory immune cells in transplantation.
od: Wood, K, et al.
Izdano: (2012)

When to refer adult patients with congenital heart disease for transplantation: Which criteria to use, which work-up?
od: Alexander Van De Bruaene, et al.
Izdano: (2021-08-01)

The where and when of T cell regulation in transplantation.
od: Issa, F, et al.
Izdano: (2013)

The where and when of T cell regulation in transplantation
od: Issa, F, et al.
Izdano: (2013)

Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use
od: Alzhrani, A, et al.
Izdano: (2020)

Regulatory B cells in transplantation: roadmaps to clinic
od: Beckett, J, et al.
Izdano: (2020)

Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy
od: Felix J. Hartmann, et al.
Izdano: (2019-07-01)

DIGITAL PMMA, WHEN AND WHICH
od: Andreea Mariana Bănățeanu, et al.
Izdano: (2024-12-01)

Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
od: Hyeyoung Lee, et al.
Izdano: (2017-01-01)

Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients
od: Dominika Deborska-Materkowska, et al.
Izdano: (2018-04-01)

Deciphering the contribution of γδ T cells to outcomes in transplantation
od: McCallion, O, et al.
Izdano: (2018)

The Exacerbation of Chronic Obstructive Pulmonary Disease: Which Symptom is Most Important to Monitor?
od: Jacobson PK, et al.
Izdano: (2023-07-01)

A CRISPR-based assay for the detection of opportunistic infections post-transplantation and for the monitoring of transplant rejection
od: Kaminski, Michael M., et al.
Izdano: (2020)

Evaluation of Minitubers Yield and Scaling which Produced from Microtubers Transplanting Using Soilless Culture Technique
od: Falah Hassan Issa
Izdano: (2017-06-01)

Cerebrovascular neuroimaging: Which tests and when?
od: Michael Hoffmann
Izdano: (1996-09-01)

Chimeric antigen receptors and regulatory T cells: the potential for HLA-specific immunosuppression in transplantation
od: Wright, S, et al.
Izdano: (2021)

Opportunities for high-plex spatial transcriptomics in solid organ transplantation
od: Cross, AR, et al.
Izdano: (2023)

Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
od: Nicola Personeni, et al.
Izdano: (2020-03-01)

Towards regulatory cellular therapies in solid organ transplantation
od: Bottomley, MJ, et al.
Izdano: (2021)

Late treatment with autologous expanded regulatory T-cell therapy after alemtuzumab induction is safe and facilitates immunosuppression minimization in living donor renal transplantation
od: Brook, MO, et al.
Izdano: (2024)

Infections in transplant “Bugs which bug transplantation in India”
od: Manisha Sahay
Izdano: (2017-01-01)

What moves where when in which languages?
od: Richards, Norvin W. (Norvin Waldemar), 1971-
Izdano: (2008)

Investigations in West Syndrome: Which, When and Why
od: Richard E Appleton
Izdano: (2015-06-01)

Characterising the immune response to combined skin and solid organ transplants
od: Stark, H
Izdano: (2022)

Editorial: Personalized nutrition with polyphenols—which, for whom, when and how?
od: Antje R. Weseler, et al.
Izdano: (2023-05-01)

IL‐33 drives the production of mouse regulatory T cells with enhanced in vivo suppressive activity in skin transplantation
od: Kawai, K, et al.
Izdano: (2020)

Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
od: Carroll, R, et al.
Izdano: (2013)

Imaging the cellular components of the immune system for advancing diagnosis and immunotherapy of cancers
od: K. Bhise, et al.
Izdano: (2021-06-01)

Extracorporial Knots in Laparoscopic Surgery: Which, When, and How
od: Omar Salem Khattab
Izdano: (2008-10-01)

Alternatives to norepinephrine in septic shock: Which agents and when?
od: Mathieu Jozwiak
Izdano: (2022-10-01)

Which Test to Perform for Cystic hydatic Diagnosis and When?
od: Zahra Arab-Mazar, et al.
Izdano: (2020-06-01)

When will European Muslim population be majority and in which country?
od: Pierre Rostan, et al.
Izdano: (2020-09-01)

Stent for Crohn’s disease strictures: Which one and when?
od: Alain Attar
Izdano: (2016-03-01)

Blood component therapy: Which, when and how much
od: Rajesh Chand Arya, et al.
Izdano: (2011-01-01)